temozolomide has been researched along with Sensitivity and Specificity in 29 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The assessment of the therapeutic response of high-grade gliomas treated with concomitant chemoradiotherapy (CCRT) using temozolomide is difficult because of the frequent occurrence of early imaging changes that are indistinguishable from tumor progression, termed pseudoprogression." | 9.16 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS, 2012) |
| "The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [(11)C]methionine (MET)." | 9.12 | Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. ( Burghaus, L; Galldiks, N; Heiss, WD; Herholz, K; Jacobs, AH; Kracht, LW; Thomas, A, 2006) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 7.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 7.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "We examined whether the amino acid PET tracers, trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) and (11)C-methyl-l-methionine ((11)C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-β (IFN), and bevacizumab (Bev) in glioblastoma." | 7.81 | Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 7.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 7.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 7.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| "This paper aims to study the value of MRI and Thallium 201 ((201)Tl) single-photon emission computed tomography (SPECT) in the prediction of overall survival (OS) in glioma patients treated with temozolomide (TMZ) and to evaluate timing of radiological follow-up." | 5.16 | MRI and thallium-201 SPECT in the prediction of survival in glioma. ( Berkhof, J; Bosma, I; Buter, J; Heimans, JJ; Hoekstra, OS; Lagerwaard, FJ; Noske, DP; Postma, TJ; Reijneveld, JC; Sanchez, E; Sizoo, EM; Vos, MJ, 2012) |
| "The assessment of the therapeutic response of high-grade gliomas treated with concomitant chemoradiotherapy (CCRT) using temozolomide is difficult because of the frequent occurrence of early imaging changes that are indistinguishable from tumor progression, termed pseudoprogression." | 5.16 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Lee, WJ; Park, CK; Park, SH; Sohn, CH; Yi, KS, 2012) |
| "The purpose of this study was to monitor the metabolic effects of temozolomide (TMZ) chemotherapy in malignant gliomas by means of repeated positron emission tomography (PET) with [(11)C]methionine (MET)." | 5.12 | Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. ( Burghaus, L; Galldiks, N; Heiss, WD; Herholz, K; Jacobs, AH; Kracht, LW; Thomas, A, 2006) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 3.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 3.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "We examined whether the amino acid PET tracers, trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) and (11)C-methyl-l-methionine ((11)C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-β (IFN), and bevacizumab (Bev) in glioblastoma." | 3.81 | Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 3.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| "Temozolomide (TMZ) is commonly used for the therapy of malignant glioma and induces thrombocytopenia in a fraction of patients." | 3.77 | Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. ( Elandt, K; Heinzl, H; Marosi, C; Preusser, M; Schwarzinger, I, 2011) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 3.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 3.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| " This method was used successfully to perform brain and plasma pharmacokinetic studies of temozolomide in mice after intraperitoneal administration." | 1.39 | Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study. ( Farinotti, R; Fernandez, C; Goldwirt, L; Zahr, N, 2013) |
| "Temozolomide was subsequently eluted with 1250 microliters of methanol (MeOH)." | 1.29 | Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. ( Biollax, J; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Shen, F, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Rosas-Alonso, R | 1 |
| Colmenarejo-Fernandez, J | 1 |
| Pernia, O | 1 |
| Rodriguez-Antolín, C | 1 |
| Esteban, I | 1 |
| Ghanem, I | 1 |
| Sanchez-Cabrero, D | 1 |
| Losantos-Garcia, I | 1 |
| Palacios-Zambrano, S | 1 |
| Moreno-Bueno, G | 1 |
| de Castro, J | 1 |
| Martinez-Marin, V | 1 |
| Ibanez-de-Caceres, I | 1 |
| Nam, JG | 1 |
| Kang, KM | 1 |
| Choi, SH | 3 |
| Lim, WH | 1 |
| Yoo, RE | 2 |
| Kim, JH | 3 |
| Yun, TJ | 2 |
| Sohn, CH | 3 |
| Perry, LA | 1 |
| Korfiatis, P | 1 |
| Agrawal, JP | 1 |
| Erickson, BJ | 1 |
| Khan, UA | 1 |
| Rennert, RC | 1 |
| White, NS | 1 |
| Bartsch, H | 1 |
| Farid, N | 1 |
| Dale, AM | 1 |
| Chen, CC | 1 |
| Goldwirt, L | 1 |
| Zahr, N | 1 |
| Farinotti, R | 1 |
| Fernandez, C | 1 |
| Jain, D | 1 |
| Athawale, R | 1 |
| Bajaj, A | 1 |
| Shrikhande, S | 1 |
| Ono, T | 1 |
| Sasajima, T | 1 |
| Doi, Y | 1 |
| Oka, S | 1 |
| Ono, M | 1 |
| Kanagawa, M | 1 |
| Baden, A | 1 |
| Mizoi, K | 1 |
| Shimizu, H | 1 |
| Kim, TM | 2 |
| Lee, SH | 2 |
| Park, CK | 2 |
| Park, SH | 2 |
| Kim, IH | 2 |
| Bulik, M | 1 |
| Kazda, T | 1 |
| Slampa, P | 1 |
| Jancalek, R | 1 |
| Roelcke, U | 1 |
| Wyss, MT | 1 |
| Nowosielski, M | 1 |
| Rudà, R | 1 |
| Roth, P | 1 |
| Hofer, S | 1 |
| Galldiks, N | 2 |
| Crippa, F | 1 |
| Weller, M | 1 |
| Soffietti, R | 1 |
| Delgado-Goñi, T | 1 |
| Ortega-Martorell, S | 1 |
| Ciezka, M | 1 |
| Olier, I | 1 |
| Candiota, AP | 1 |
| Julià-Sapé, M | 1 |
| Fernández, F | 1 |
| Pumarola, M | 1 |
| Lisboa, PJ | 1 |
| Arús, C | 1 |
| McCann, CM | 1 |
| Waterman, P | 1 |
| Figueiredo, JL | 1 |
| Aikawa, E | 1 |
| Weissleder, R | 1 |
| Chen, JW | 1 |
| Andrasi, M | 1 |
| Bustos, R | 1 |
| Gaspar, A | 1 |
| Gomez, FA | 1 |
| Klekner, A | 1 |
| Preusser, M | 1 |
| Elandt, K | 1 |
| Schwarzinger, I | 1 |
| Marosi, C | 1 |
| Heinzl, H | 1 |
| Payer, F | 1 |
| Vos, MJ | 2 |
| Berkhof, J | 1 |
| Hoekstra, OS | 1 |
| Bosma, I | 1 |
| Sizoo, EM | 1 |
| Heimans, JJ | 2 |
| Reijneveld, JC | 1 |
| Sanchez, E | 1 |
| Lagerwaard, FJ | 1 |
| Buter, J | 1 |
| Noske, DP | 1 |
| Postma, TJ | 2 |
| Yang, S | 1 |
| Savvides, P | 1 |
| Liu, L | 1 |
| Gerson, SL | 1 |
| Xu, Y | 1 |
| Lee, WJ | 1 |
| Yi, KS | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Rinne, M | 1 |
| Caldwell, D | 1 |
| Kelley, MR | 1 |
| Ueno, T | 1 |
| Ko, SH | 1 |
| Grubbs, E | 1 |
| Pruitt, SK | 1 |
| Friedman, HS | 2 |
| Tyler, DS | 1 |
| Kracht, LW | 1 |
| Burghaus, L | 1 |
| Thomas, A | 1 |
| Jacobs, AH | 1 |
| Heiss, WD | 1 |
| Herholz, K | 1 |
| Stupp, R | 1 |
| Hegi, ME | 1 |
| Maxwell, J | 1 |
| Shen, F | 1 |
| Decosterd, LA | 1 |
| Gander, M | 1 |
| Leyvraz, S | 1 |
| Biollax, J | 1 |
| Lejeune, F | 1 |
| Kim, HK | 1 |
| Lin, CC | 1 |
| Parker, D | 1 |
| Veals, J | 1 |
| Lim, J | 1 |
| Likhari, P | 1 |
| Statkevich, P | 1 |
| Marco, A | 1 |
| Nomeir, AA | 1 |
| Faraoni, I | 1 |
| Turriziani, M | 1 |
| Masci, G | 1 |
| De Vecchis, L | 1 |
| Shay, JW | 1 |
| Bonmassar, E | 1 |
| Graziani, G | 1 |
| Harrison, KL | 1 |
| Wood, M | 1 |
| Lees, NP | 1 |
| Hall, CN | 1 |
| Margison, GP | 1 |
| Povey, AC | 1 |
| Gomez-Manzano, C | 1 |
| Lemoine, MG | 1 |
| Hu, M | 1 |
| He, J | 1 |
| Mitlianga, P | 1 |
| Liu, TJ | 1 |
| Yung, AW | 1 |
| Fueyo, J | 1 |
| Groves, MD | 1 |
1 review available for temozolomide and Sensitivity and Specificity
| Article | Year |
|---|---|
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
4 trials available for temozolomide and Sensitivity and Specificity
| Article | Year |
|---|---|
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female | 2015 |
MRI and thallium-201 SPECT in the prediction of survival in glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2012 |
Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Artifacts; Brain Neoplasms; Chemoradioth | 2012 |
Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Methionin | 2006 |
24 other studies available for temozolomide and Sensitivity and Specificity
| Article | Year |
|---|---|
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; | 2017 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2018 |
Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Femal | 2018 |
Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study.
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Dacarbazine; Female; Least-Squares A | 2013 |
Double-salting out assisted liquid-liquid extraction (SALLE) HPLC method for estimation of temozolomide from biological samples.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Dacarbazine; Humans; Linear Models; Liquid-Liqu | 2014 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine | 2015 |
Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Topics: Adult; Amino Acids; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Dacarbazine; Disease-F | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Da | 2016 |
Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioma; | 2009 |
Analysis and stability study of temozolomide using capillary electrophoresis.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents, Alkylating; Chromatography, Micellar Electrokinet | 2010 |
Immature and absolute platelet count changes and thrombocytopenia in malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Austria; Blood Platelets; Dacarbazine; Female; Gliom | 2011 |
Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Chromatography, Liquid; Clinical Tria | 2012 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells.
Topics: Adenoviridae; Alkylating Agents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Br | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Per | 2004 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Stagin | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2007 |
Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Dacarbazine; Drug Stability; Humans; Hy | 1995 |
High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Circa | 1997 |
Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Division; Cell Sur | 1997 |
Development and application of a sensitive and rapid immunoassay for the quantitation of N7-methyldeoxyguanosine in DNA samples.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain; Dacarbazine; Deoxyguanosine; DNA Addu | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |